** Scholar Rock's shares SRRK.O up 3.4% premarket
** Co says U.S. FDA accepts SRRK's drug, apitegromab, for priority review with a decision expected by Sept 22; EU's medicines regulator has also accepted drug for review
** Co's drug treats spinal muscular atrophy, which stops production of a protein necessary for neuromuscular development and leaves children too weak to walk, talk and swallow
** In a late-stage study, patients given apitegromab saw better improvement in motor function than those given a placebo
** As of last close, SRRK up nearly 17% so far this year
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。